| Fanyi Kong, MD | |
|
2811 208th St, Bayside, NY 11360-2420 | |
| (917) 655-4693 | |
| Not Available |
| Full Name | Fanyi Kong |
|---|---|
| Gender | Male |
| Speciality | Pathology |
| Experience | 42 Years |
| Location | 2811 208th St, Bayside, New York |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1528131596 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207ZP0102X | Pathology - Anatomic Pathology & Clinical Pathology | 223594 (New York) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Staten Island University Hospital | Staten island, NY | Hospital |
| Bronx Health System | Bronx, NY | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| North Shore Digestive Medicine Pc | 2860642592 | 6 |
| North Shore - Lij Medical Pc | 3375701568 | 5099 |
| Bronxcare Health System | 3870404429 | 270 |
| Diamond Medical Group Pc | 7214826916 | 8 |
News Archive
The researchers, from the Liggins Institute at the University of Auckland, found that bone retains a "memory" of exercise's effects long after the exercise is ceased, and this bone memory continues to change the way the body metabolizes a high-fat diet, and published these results in Frontiers in Physiology.
A new study published in the journal JAMA Cardiology in April 2020 reports that patients with hypertension who are taking medications called ACE inhibitors (ACEI) or ARBs are not at higher risk for death or more severe illness with COVID-19. This conclusion supports current guidelines for the treatment of hypertension during this pandemic.
The recall comes as a sharp blow to Affymax, a small biotechnology firm based in Palo Alto, Calif., that developed Omontys and has no other late-stage drugs in its pipeline.
Isis Pharmaceuticals, Inc. announced today positive results from a Phase 1 study with ISIS-PKKRx. In this study, healthy volunteers treated with ISIS-PKKRx achieved dose-dependent reductions of up to 95 percent in prekallikrein, or PKK. ISIS-PKKRx is a RNA-targeted antisense drug designed to inhibit the production of PKK for the prophylactic treatment of hereditary angioedema (HAE).
New research from Rockefeller University, performed in collaboration with scientists at Duke University in North Carolina, reveals for the first time that this extreme variability in peopl's perception of androstenone is due in large part to genetic variations in a single odorant receptor called OR7D4.
› Verified 4 days ago
| Entity Name | Diamond Medical Group Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1760664395 PECOS PAC ID: 7214826916 Enrollment ID: O20040311000947 |
News Archive
The researchers, from the Liggins Institute at the University of Auckland, found that bone retains a "memory" of exercise's effects long after the exercise is ceased, and this bone memory continues to change the way the body metabolizes a high-fat diet, and published these results in Frontiers in Physiology.
A new study published in the journal JAMA Cardiology in April 2020 reports that patients with hypertension who are taking medications called ACE inhibitors (ACEI) or ARBs are not at higher risk for death or more severe illness with COVID-19. This conclusion supports current guidelines for the treatment of hypertension during this pandemic.
The recall comes as a sharp blow to Affymax, a small biotechnology firm based in Palo Alto, Calif., that developed Omontys and has no other late-stage drugs in its pipeline.
Isis Pharmaceuticals, Inc. announced today positive results from a Phase 1 study with ISIS-PKKRx. In this study, healthy volunteers treated with ISIS-PKKRx achieved dose-dependent reductions of up to 95 percent in prekallikrein, or PKK. ISIS-PKKRx is a RNA-targeted antisense drug designed to inhibit the production of PKK for the prophylactic treatment of hereditary angioedema (HAE).
New research from Rockefeller University, performed in collaboration with scientists at Duke University in North Carolina, reveals for the first time that this extreme variability in peopl's perception of androstenone is due in large part to genetic variations in a single odorant receptor called OR7D4.
› Verified 4 days ago
| Entity Name | Bronxcare Health System |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1245390855 PECOS PAC ID: 3870404429 Enrollment ID: O20040526001082 |
News Archive
The researchers, from the Liggins Institute at the University of Auckland, found that bone retains a "memory" of exercise's effects long after the exercise is ceased, and this bone memory continues to change the way the body metabolizes a high-fat diet, and published these results in Frontiers in Physiology.
A new study published in the journal JAMA Cardiology in April 2020 reports that patients with hypertension who are taking medications called ACE inhibitors (ACEI) or ARBs are not at higher risk for death or more severe illness with COVID-19. This conclusion supports current guidelines for the treatment of hypertension during this pandemic.
The recall comes as a sharp blow to Affymax, a small biotechnology firm based in Palo Alto, Calif., that developed Omontys and has no other late-stage drugs in its pipeline.
Isis Pharmaceuticals, Inc. announced today positive results from a Phase 1 study with ISIS-PKKRx. In this study, healthy volunteers treated with ISIS-PKKRx achieved dose-dependent reductions of up to 95 percent in prekallikrein, or PKK. ISIS-PKKRx is a RNA-targeted antisense drug designed to inhibit the production of PKK for the prophylactic treatment of hereditary angioedema (HAE).
New research from Rockefeller University, performed in collaboration with scientists at Duke University in North Carolina, reveals for the first time that this extreme variability in peopl's perception of androstenone is due in large part to genetic variations in a single odorant receptor called OR7D4.
› Verified 4 days ago
| Entity Name | Downtown Gastroenterology Associates Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1003976960 PECOS PAC ID: 1658341474 Enrollment ID: O20040729000251 |
News Archive
The researchers, from the Liggins Institute at the University of Auckland, found that bone retains a "memory" of exercise's effects long after the exercise is ceased, and this bone memory continues to change the way the body metabolizes a high-fat diet, and published these results in Frontiers in Physiology.
A new study published in the journal JAMA Cardiology in April 2020 reports that patients with hypertension who are taking medications called ACE inhibitors (ACEI) or ARBs are not at higher risk for death or more severe illness with COVID-19. This conclusion supports current guidelines for the treatment of hypertension during this pandemic.
The recall comes as a sharp blow to Affymax, a small biotechnology firm based in Palo Alto, Calif., that developed Omontys and has no other late-stage drugs in its pipeline.
Isis Pharmaceuticals, Inc. announced today positive results from a Phase 1 study with ISIS-PKKRx. In this study, healthy volunteers treated with ISIS-PKKRx achieved dose-dependent reductions of up to 95 percent in prekallikrein, or PKK. ISIS-PKKRx is a RNA-targeted antisense drug designed to inhibit the production of PKK for the prophylactic treatment of hereditary angioedema (HAE).
New research from Rockefeller University, performed in collaboration with scientists at Duke University in North Carolina, reveals for the first time that this extreme variability in peopl's perception of androstenone is due in large part to genetic variations in a single odorant receptor called OR7D4.
› Verified 4 days ago
| Entity Name | Physicians Of University Hospital Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1417901323 PECOS PAC ID: 5890877542 Enrollment ID: O20080204000002 |
News Archive
The researchers, from the Liggins Institute at the University of Auckland, found that bone retains a "memory" of exercise's effects long after the exercise is ceased, and this bone memory continues to change the way the body metabolizes a high-fat diet, and published these results in Frontiers in Physiology.
A new study published in the journal JAMA Cardiology in April 2020 reports that patients with hypertension who are taking medications called ACE inhibitors (ACEI) or ARBs are not at higher risk for death or more severe illness with COVID-19. This conclusion supports current guidelines for the treatment of hypertension during this pandemic.
The recall comes as a sharp blow to Affymax, a small biotechnology firm based in Palo Alto, Calif., that developed Omontys and has no other late-stage drugs in its pipeline.
Isis Pharmaceuticals, Inc. announced today positive results from a Phase 1 study with ISIS-PKKRx. In this study, healthy volunteers treated with ISIS-PKKRx achieved dose-dependent reductions of up to 95 percent in prekallikrein, or PKK. ISIS-PKKRx is a RNA-targeted antisense drug designed to inhibit the production of PKK for the prophylactic treatment of hereditary angioedema (HAE).
New research from Rockefeller University, performed in collaboration with scientists at Duke University in North Carolina, reveals for the first time that this extreme variability in peopl's perception of androstenone is due in large part to genetic variations in a single odorant receptor called OR7D4.
› Verified 4 days ago
| Entity Name | North Shore - Lij Medical Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1053688572 PECOS PAC ID: 3375701568 Enrollment ID: O20120220000262 |
News Archive
The researchers, from the Liggins Institute at the University of Auckland, found that bone retains a "memory" of exercise's effects long after the exercise is ceased, and this bone memory continues to change the way the body metabolizes a high-fat diet, and published these results in Frontiers in Physiology.
A new study published in the journal JAMA Cardiology in April 2020 reports that patients with hypertension who are taking medications called ACE inhibitors (ACEI) or ARBs are not at higher risk for death or more severe illness with COVID-19. This conclusion supports current guidelines for the treatment of hypertension during this pandemic.
The recall comes as a sharp blow to Affymax, a small biotechnology firm based in Palo Alto, Calif., that developed Omontys and has no other late-stage drugs in its pipeline.
Isis Pharmaceuticals, Inc. announced today positive results from a Phase 1 study with ISIS-PKKRx. In this study, healthy volunteers treated with ISIS-PKKRx achieved dose-dependent reductions of up to 95 percent in prekallikrein, or PKK. ISIS-PKKRx is a RNA-targeted antisense drug designed to inhibit the production of PKK for the prophylactic treatment of hereditary angioedema (HAE).
New research from Rockefeller University, performed in collaboration with scientists at Duke University in North Carolina, reveals for the first time that this extreme variability in peopl's perception of androstenone is due in large part to genetic variations in a single odorant receptor called OR7D4.
› Verified 4 days ago
| Entity Name | North Shore Digestive Medicine Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1407114960 PECOS PAC ID: 2860642592 Enrollment ID: O20121015000668 |
News Archive
The researchers, from the Liggins Institute at the University of Auckland, found that bone retains a "memory" of exercise's effects long after the exercise is ceased, and this bone memory continues to change the way the body metabolizes a high-fat diet, and published these results in Frontiers in Physiology.
A new study published in the journal JAMA Cardiology in April 2020 reports that patients with hypertension who are taking medications called ACE inhibitors (ACEI) or ARBs are not at higher risk for death or more severe illness with COVID-19. This conclusion supports current guidelines for the treatment of hypertension during this pandemic.
The recall comes as a sharp blow to Affymax, a small biotechnology firm based in Palo Alto, Calif., that developed Omontys and has no other late-stage drugs in its pipeline.
Isis Pharmaceuticals, Inc. announced today positive results from a Phase 1 study with ISIS-PKKRx. In this study, healthy volunteers treated with ISIS-PKKRx achieved dose-dependent reductions of up to 95 percent in prekallikrein, or PKK. ISIS-PKKRx is a RNA-targeted antisense drug designed to inhibit the production of PKK for the prophylactic treatment of hereditary angioedema (HAE).
New research from Rockefeller University, performed in collaboration with scientists at Duke University in North Carolina, reveals for the first time that this extreme variability in peopl's perception of androstenone is due in large part to genetic variations in a single odorant receptor called OR7D4.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Fanyi Kong, MD 2811 208th St, Bayside, NY 11360-2420 Ph: (917) 655-4693 | Fanyi Kong, MD 2811 208th St, Bayside, NY 11360-2420 Ph: (917) 655-4693 |
News Archive
The researchers, from the Liggins Institute at the University of Auckland, found that bone retains a "memory" of exercise's effects long after the exercise is ceased, and this bone memory continues to change the way the body metabolizes a high-fat diet, and published these results in Frontiers in Physiology.
A new study published in the journal JAMA Cardiology in April 2020 reports that patients with hypertension who are taking medications called ACE inhibitors (ACEI) or ARBs are not at higher risk for death or more severe illness with COVID-19. This conclusion supports current guidelines for the treatment of hypertension during this pandemic.
The recall comes as a sharp blow to Affymax, a small biotechnology firm based in Palo Alto, Calif., that developed Omontys and has no other late-stage drugs in its pipeline.
Isis Pharmaceuticals, Inc. announced today positive results from a Phase 1 study with ISIS-PKKRx. In this study, healthy volunteers treated with ISIS-PKKRx achieved dose-dependent reductions of up to 95 percent in prekallikrein, or PKK. ISIS-PKKRx is a RNA-targeted antisense drug designed to inhibit the production of PKK for the prophylactic treatment of hereditary angioedema (HAE).
New research from Rockefeller University, performed in collaboration with scientists at Duke University in North Carolina, reveals for the first time that this extreme variability in peopl's perception of androstenone is due in large part to genetic variations in a single odorant receptor called OR7D4.
› Verified 4 days ago
Gang He, MD, PHD, FCAP Pathology Medicare: Accepting Medicare Assignments Practice Location: 4534 Bell Blvd, 2nd Floor, Bayside, NY 11361 Phone: 718-279-1271 Fax: 718-279-1092 |